Highlights:
-Largest anticoagulant trial in atrial fibrillation shows edoxaban is as effective as warfarin
-New generation pacemakers reduce atrial fibrillation progression by 61% at two years
-Ablation of persistent atrial fibrillation, are we there yet?
-Profile: Anne Curtis
[pdfviewer width=”100%” height=”940px” beta=”true”]https://cardiacrhythmnews.com/wp-content/uploads/sites/12/2016/06/23-Cardiac-Rhythm-News.pdf[/pdfviewer]